NGL Fine-Chem Limited (NGLFINE.BO)
INR 1132.25
(-5.0%)
INR 1132.25
(-5.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 678.68 Million INR | 33.67% |
| 2022 | 404.87 Million INR | -49.25% |
| 2021 | 788.78 Million INR | -9.96% |
| 2020 | 881.27 Million INR | 253.32% |
| 2019 | 228.09 Million INR | -36.97% |
| 2018 | 361.53 Million INR | 67.01% |
| 2017 | 241.29 Million INR | -9.2% |
| 2016 | 268.97 Million INR | 18.66% |
| 2015 | 221.58 Million INR | 47.11% |
| 2014 | 170.05 Million INR | 34.05% |
| 2013 | 106.12 Million INR | 45.72% |
| 2012 | 75.58 Million INR | 97.69% |
| 2011 | 38.31 Million INR | -28.35% |
| 2010 | 53.46 Million INR | 7.12% |
| 2009 | 49.91 Million INR | 15.11% |
| 2008 | 43.36 Million INR | 279.68% |
| 2007 | 11.42 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 93.5 Million INR | -21.88% |
| 2023 Q4 | 158.22 Million INR | -9.83% |
| 2023 FY | - INR | 33.67% |
| 2023 Q1 | 131.85 Million INR | -12.5% |
| 2023 Q2 | 171.88 Million INR | 30.36% |
| 2023 Q3 | 175.47 Million INR | 2.09% |
| 2022 Q1 | 46.43 Million INR | -62.44% |
| 2022 Q3 | 105.01 Million INR | 9.16% |
| 2022 Q2 | 96.2 Million INR | 107.16% |
| 2022 Q4 | 150.68 Million INR | 43.49% |
| 2022 FY | - INR | -49.25% |
| 2021 Q3 | 163.38 Million INR | -24.21% |
| 2021 Q4 | 123.63 Million INR | -24.33% |
| 2021 Q1 | 281.17 Million INR | 21.81% |
| 2021 FY | - INR | -9.96% |
| 2021 Q2 | 215.56 Million INR | -23.33% |
| 2020 FY | - INR | 253.32% |
| 2020 Q2 | 231.68 Million INR | 48.23% |
| 2020 Q4 | 230.82 Million INR | -10.9% |
| 2020 Q3 | 259.05 Million INR | 11.81% |
| 2020 Q1 | 156.29 Million INR | 189.93% |
| 2019 FY | - INR | -36.97% |
| 2019 Q4 | 53.9 Million INR | 22.02% |
| 2019 Q1 | 98.02 Million INR | -34.4% |
| 2019 Q3 | 44.17 Million INR | -17.62% |
| 2019 Q2 | 53.62 Million INR | -45.29% |
| 2018 Q4 | 149.42 Million INR | 84.27% |
| 2018 FY | - INR | 67.01% |
| 2018 Q2 | 87.36 Million INR | 16.2% |
| 2018 Q1 | 75.17 Million INR | 13.38% |
| 2018 Q3 | 81.09 Million INR | -7.18% |
| 2017 Q2 | 69.51 Million INR | 125.1% |
| 2017 Q4 | 66.3 Million INR | -4.93% |
| 2017 FY | - INR | -9.2% |
| 2017 Q3 | 69.74 Million INR | 0.33% |
| 2017 Q1 | 30.88 Million INR | -51.14% |
| 2016 Q1 | 72.33 Million INR | 10.14% |
| 2016 FY | - INR | 18.66% |
| 2016 Q3 | 73.65 Million INR | 36.6% |
| 2016 Q4 | 63.19 Million INR | -14.19% |
| 2016 Q2 | 53.91 Million INR | -25.46% |
| 2015 Q1 | 53.06 Million INR | -0.33% |
| 2015 Q3 | 49.17 Million INR | -2.7% |
| 2015 Q4 | 65.67 Million INR | 33.56% |
| 2015 FY | - INR | 47.11% |
| 2015 Q2 | 50.53 Million INR | -4.76% |
| 2014 Q2 | 41.62 Million INR | 6.44% |
| 2014 Q4 | 53.23 Million INR | 266.53% |
| 2014 FY | - INR | 34.05% |
| 2014 Q1 | 39.1 Million INR | 92.02% |
| 2014 Q3 | 14.52 Million INR | -65.11% |
| 2013 Q2 | 32.14 Million INR | -4.34% |
| 2013 Q4 | 20.36 Million INR | -0.72% |
| 2013 FY | - INR | 45.72% |
| 2013 Q3 | 20.51 Million INR | -36.19% |
| 2013 Q1 | 33.6 Million INR | 42.36% |
| 2012 Q1 | 21.18 Million INR | 72.54% |
| 2012 FY | - INR | 97.69% |
| 2012 Q4 | 23.6 Million INR | 36.7% |
| 2012 Q3 | 17.27 Million INR | 32.27% |
| 2012 Q2 | 13.05 Million INR | -38.36% |
| 2011 Q3 | 8.38 Million INR | 0.0% |
| 2011 Q4 | 12.27 Million INR | 46.48% |
| 2011 FY | - INR | -28.35% |
| 2010 FY | - INR | 7.12% |
| 2009 FY | - INR | 15.11% |
| 2008 Q4 | 15.47 Million INR | 0.0% |
| 2008 FY | - INR | 279.68% |
| 2007 FY | - INR | 0.0% |
| 2007 Q4 | 6.69 Million INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott India Limited | 16.97 Billion INR | 96.003% |
| Cipla Limited | 67.19 Billion INR | 98.99% |
| Gland Pharma Limited | 15.03 Billion INR | 95.485% |
| GlaxoSmithKline Pharmaceuticals Limited | 8.87 Billion INR | 92.351% |
| Kopran Limited | 890.24 Million INR | 23.764% |
| Marksans Pharma Limited | 4.58 Billion INR | 85.2% |
| Pfizer Limited | 8.23 Billion INR | 91.761% |
| Sanofi India Limited | 8.86 Billion INR | 92.347% |
| SMS Pharmaceuticals Limited | 1.21 Billion INR | 43.947% |